GENMAB A/SGMABEarnings & Financial Report
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
Revenue
$604.5M
Gross Profit
$601.5M
Operating Profit
$212.9M
Net Profit
$193.6M
Gross Margin
99.5%
Operating Margin
35.2%
Net Margin
32.0%
YoY Growth
31.8%
GENMAB A/S Q2 FY2023 Financial Summary
GENMAB A/S reported revenue of $604.5M (up 31.8% YoY) for Q2 FY2023, with a net profit of $193.6M (down 29.4% YoY) (32.0% margin). Cost of goods sold was $3.0M, operating expenses totaled $388.6M.
Key Financial Metrics
| Total Revenue | $604.5M |
|---|---|
| Net Profit | $193.6M |
| Gross Margin | 99.5% |
| Operating Margin | 35.2% |
| Report Period | Q2 FY2023 |
GENMAB A/S Quarterly Revenue & Net Profit History
GENMAB A/S results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $925.0M | +18.7% | $336.0M | 36.3% |
| Q2 FY2024 | $779.0M | +28.9% | $203.0M | 26.1% |
| Q2 FY2023 | $604.5M | +31.8% | $193.6M | 32.0% |
| Q2 FY2022 | $458.5M | +60.3% | $274.2M | 59.8% |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $458.5M | $604.5M | $779.0M | $925.0M |
| YoY Growth | 60.3% | 31.8% | 28.9% | 18.7% |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Assets | $3.98B | $4.64B | $5.60B | $6.46B |
| Liabilities | $434.1M | $467.3M | $1.11B | $1.16B |
| Equity | $3.55B | $4.14B | $4.45B | $5.30B |
Cash Flow
| Q2 2024 | Q2 2025 | |
|---|---|---|
| Operating CF | $438.0M | $349.0M |